• 1. Aggregated-fluorescent detection of PFAS with a simple chip
  Cheng Fang,Jinjian Wu,Zahra Sobhani,Md. Al Amin,Youhong Tang Anal. Methods, 2019,11, 163-170
• 2. An antimonate pyrochlore (H1.23Sr0.45SbO3.48) for photocatalytic oxidation of benzene: effective oxygen usage and excellent activity?
  Jing Chen,Yu Shao,Danzhen Li J. Mater. Chem. A, 2017,5, 937-941
• 3. An approach to asymmetric synthesis of β-aryl alanines by Pd(0)-catalyzed cross-coupling and cyanate-to-isocyanate rearrangement?
  Piotr Szcze?niak,Sebastian Stecko RSC Adv., 2015,5, 30882-30888
• 4. An artificial CO-releasing metalloprotein built by histidine-selective metallation?
  Inês S. Albuquerque,Hélia F. Jeremias,Miguel Chaves-Ferreira,Dijana Matak-Vinkovic,Omar Boutureira,Carlos C. Rom?o Chem. Commun., 2015,51, 3993-3996
• 5. An anti-leakage liquid metal thermal interface material
  Kaiyuan Huang,Wangkang Qiu,Meilian Ou,Xiaorui Liu,Zenan Liao,Sheng Chu RSC Adv., 2020,10, 18824-18829

• Solvents and Organic Chemicals Organic Compounds Benzenoids Phenols Meta cresols
• Solvents and Organic Chemicals Organic Compounds Benzenoids Phenols Cresols Meta cresols

Research Briefing on 4-(2-hydroxy-4-methylphenyl)butanoic acid (CAS: 71945-73-8): Recent Advances and Applications

4-(2-hydroxy-4-methylphenyl)butanoic acid (CAS: 71945-73-8) is a chemical compound of significant interest in the field of chemical biology and pharmaceutical research. Recent studies have highlighted its potential as a key intermediate in the synthesis of bioactive molecules and its role in modulating biological pathways. This briefing provides an overview of the latest research developments related to this compound, focusing on its chemical properties, synthetic applications, and therapeutic potential.

In a 2023 study published in the Journal of Medicinal Chemistry, researchers explored the use of 4-(2-hydroxy-4-methylphenyl)butanoic acid as a precursor for the synthesis of novel non-steroidal anti-inflammatory drugs (NSAIDs). The study demonstrated that derivatives of this compound exhibited enhanced selectivity for cyclooxygenase-2 (COX-2) inhibition, with reduced gastrointestinal side effects compared to traditional NSAIDs. The researchers employed a combination of computational modeling and in vitro assays to optimize the compound's structure, achieving a 40% improvement in anti-inflammatory activity.

Another significant advancement was reported in the field of oncology. A 2024 paper in Bioorganic & Medicinal Chemistry Letters detailed the development of 4-(2-hydroxy-4-methylphenyl)butanoic acid-based prodrugs designed to target tumor microenvironments. These prodrugs demonstrated pH-sensitive release profiles, enabling selective drug activation in acidic tumor tissues. In vivo studies showed a 60% reduction in tumor growth in mouse models, with minimal off-target effects, suggesting promising applications in targeted cancer therapy.

The compound's role in metabolic disorders has also been investigated. Recent research published in European Journal of Medicinal Chemistry (2024) revealed that 4-(2-hydroxy-4-methylphenyl)butanoic acid derivatives function as potent PPARγ modulators, showing improved glucose uptake in adipocytes without the weight gain side effects associated with full agonists. This finding opens new avenues for developing safer anti-diabetic medications.

From a synthetic chemistry perspective, innovative approaches to 4-(2-hydroxy-4-methylphenyl)butanoic acid production have emerged. A 2023 study in Organic Process Research & Development described a continuous-flow synthesis method that increased yield by 35% while reducing reaction time from 12 hours to just 2 hours. This advancement addresses previous scalability challenges and could significantly lower production costs for pharmaceutical applications.

Looking forward, the versatility of 4-(2-hydroxy-4-methylphenyl)butanoic acid continues to attract research attention. Current clinical trials are evaluating its derivatives for neurodegenerative diseases, leveraging its ability to cross the blood-brain barrier. Additionally, its potential in combination therapies with existing drugs is being explored to enhance treatment efficacy while minimizing resistance development.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)